Moreover, complement component 3 (C3) protein-associated liposomal formulation has been fabricated for targeted APC activation in the absence of specific tumor antigens (Figure 1G) [40,84], due to the priming efficacy of C3 through the complement receptors: (1) active encapsulation of foreign particles, and (2) increased uptake into myeloid cells [40]. This evidence concerns the gene C3 and neoplasm.